AI-Powered Research

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
George Washington University Biostatistics Center, Rockville, Maryland, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 13 locations

Cognition, Steroids, and Imaging in Cushings Disease

Completed

Conditions: Cushing Syndrome

First Posted Date: 2004-04-12

Last Posted Date: 2010-02-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT00081341

Locations: 🇺🇸
General Clinical Research Center, University of Michigan Health System, Ann Arbor, Michigan, United States

Early Detection of Barrett's Esophagus

Completed

Conditions: Barrett's Esophagus

First Posted Date: 2004-04-09

Last Posted Date: 2020-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 737

Registration Number: NCT00081354

Locations: 🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: triapine
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2004-04-08

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00081276

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: fluorouracil
Drug: oxaliplatin
Drug: leucovorin calcium

First Posted Date: 2004-04-08

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00080990

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Drug: fenretinide
Other: laboratory biomarker analysis

First Posted Date: 2004-04-08

Last Posted Date: 2015-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00080899

Locations: 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States

Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck

Phase 1

Terminated

Conditions: Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Salivary Gland Squamous Cell Carcinoma
Stage III Salivary Gland Cancer
Stage III Squamous Cell Carcinoma of the Hypopharynx

Interventions: Biological: PV701

First Posted Date: 2004-04-08

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00081211

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Biological: oblimersen sodium
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2004-04-08

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 160

Registration Number: NCT00080847

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Home Terms & Conditions Privacy Policy